Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Yuya Seko,1 Taichiro Nishikawa,1 Atsushi Umemura,1 Kanji Yamaguchi,1 Michihisa Moriguchi,1 Kohichiroh Yasui,1 Mayumi Kimura,2 Hiroaki Iijima,3 Toshio Hashimoto,3 Yoshio Sumida,4 Takeshi Okanoue,5 Yoshito Itoh1 1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine,...

Full description

Bibliographic Details
Main Authors: Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:
canagliflozin
Japanese
NASH
fibrosis stages
SGLT2 inhibitor
type 2 diabetes mellitus
Online Access:https://www.dovepress.com/efficacy-and-safety-of-canagliflozin-in-type-2-diabetes-mellitus-patie-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/efficacy-and-safety-of-canagliflozin-in-type-2-diabetes-mellitus-patie-peer-reviewed-article-DMSO

Similar Items